学校主页 |
副高

王鹏

副教授、硕士生导师

研究方向:肿瘤流行病学、肿瘤诊断、肿瘤免疫学


联系电话:0371-67781453

邮箱:wangpeng@zzu.edu.cn


一、基本介绍


王鹏,女,副教授,硕士生导师。中国抗癌协会河南省精准肿瘤医学青年委员会常务委员、河南省免疫学会感染与分子免疫学专业委员会常务委员等。获河南省科技进步二等奖4项,河南省科普成果一等奖1项、二等奖1项。发表SCI收录论文70,授权国家发明专利1项,参编著作2部。


二、教育/工作经历

工作经历:

[1] 2019-至今,郑州大学公共卫生学院,副教授

[2] 2012-2019,郑州大学,公共卫生学院,讲师

[3] 2007-2011,郑州大学公共卫生学院,助教


教育经历:

[1] 2015-2019,西安交通大学,流行病与卫生统计学专业,博士

[2] 2004-2007,郑州大学,流行病与卫生统计学专业,硕士

[3] 1999-2004,郑州大学,预防医学,本科



三、学术荣誉/学术兼职

l 学术荣誉

[1] 基于自身抗体的乳腺癌和卵巢癌早期诊断标志物发现和应用,2023,河南省科技进步二等奖,第

[2] 肿瘤相关抗原抗体系统用于肺癌早期免疫诊断的评价,2019,河南省科技进步二等奖,第

[3] 肿瘤相关抗原的分子鉴定与评价及在肝癌早期免疫诊断中的应用,2017,河南省科技进步二等奖, 第

[4] 单核苷酸多态性及基因-环境交互作用与食管鳞癌遗传易感性,2018河南省科技进步二等奖, 第

[5] 河南省常见消化道恶性肿瘤肝癌的早期诊断新技术的推广和应用,2016,河南省科技普及成果奖,第

[6] 河南省心血管疾病危险因素分析及推广,2016, 河南省科技普及成果奖二等奖, 第


l 国内学会与学术期刊

l 中国抗癌协会 河南省精准肿瘤医学青年委员会常务委员

l 河南省抗癌协会 肿瘤流行病与病因学专业委员会青年委员会委员

l 河南省免疫学会 感染与分子免疫学专业委员会常务委员

l 南省预防医学会 肿瘤预防与控制专业委员会委员


四、主持科研项目


[1] 河南省高层次人才国际化培养资助项目(年限:2021-2022):基于HuProtTM人类全蛋白质组芯片筛选食管癌相关抗原及诊断模型的构建

[2] 河南省重点研发与推广专项(编号:192102310042;年限:2019-2020):基于癌症驱动基因的蛋白芯片筛选食管癌相关抗原及自身抗体在其早期诊断中的应用价值

[3] 郑州市协同创新重大专项“食管癌早期免疫诊断关键技术研发和应用”子课题(编号:18XTZX12007,年限:2019-2023):食管癌相关TAA 的验证和确证(蛋白芯片定制和ELISA)

[4] 国家科技重大专项乙肝相关肝癌早期免疫诊断关键技术研发和应用”子项目(编号:2018ZX10302205-004;年限2018-2020):SERPASEREX筛选乙肝相关肝癌TAAs

[5] 河南省重大科技专项“基于精准医学的常见恶性肿瘤早期免疫和分子诊断关键技术研发和应用”子课题(编号:161100311400;年限2016-2019):基于生物信息数据库筛选食管癌相关基因及其自身抗体在食管癌早期诊断中的价值

[6] 河南省重点科技攻关项目(编号:162102310037;年限2016-2017):肿瘤相关抗原微阵列芯片技术在食管癌早期诊断中的应用研究

[7] 河南省医学科技攻关计划项目(编号:201503201;年限2015-2016):基于GWAS和蛋白质组学的结直肠癌标志物的研究和评价

五、代表性成果


l 论文

[1] Sun GY, Chen HL, Xia JF, Ye H, Li TD, Li JX, Zhang XY, Cheng YF, Wang KY, Shi JX, Wang P*. Diagnostic performance of anti-MAGEA family protein autoantibodies in esophageal squamous cell carcinoma. International Immunopharmacology, 2023, 125(Pt A): 111041.

[2] Yang Q, Ye H, Sun GY, Wang KY, Dai LP, Qiu CP, Shi JX, Zhu JC, Wang X, Wang P*. Human Proteome Microarray identifies autoantibodies to tumor-associated antigens as serological biomarkers for the diagnosis of hepatocellular carcinoma. Molecular Oncology, 2023, 17(5): 887-900.

[3] Sun GY, Ye H, Liu HJ, Li TD, Li JX, Zhang XY, Cheng YF, Wang KY, Shi JX, Dai LP, Wang P*. ZPR1 is an immunodiagnostic biomarker and promotes the tumor progression in esophageal squamous cell carcinoma. Cancer Science, 2023, doi: 10.1111/cas.16004.

[4] Sun GY, Ye H, Yang Q, Zhu JC, Qiu CP, Shi JX, Dai LP, Wang KY, Zhang JY, Wang P*. Using proteome microarray and gene expression omnibus database to screen tumour-associated antigens to construct the optimal diagnostic model of oesophageal squamous cell carcinoma. Clinical Oncology, 2023, 35(10): e582-e592.

[5] Xie WH, Sui GY, Xia JX, Chen HL, Wang C, Lin J, Wang P*. Identification of novel tumor associated antigens and evaluation of a panel of autoantibodies in detecting oral cancer. BMC Cancer, 2023, 23(1): 802.

[6] Li JX, Chen HL, Sun GY, Zhang XY, Ye H, Wang P*. Role of miR-21 in the diagnosis of colorectal cancer: meta-analysis and bioinformatics. Pathology Research and Practice, 2023, 248: 154670.

[7] Wang KY, Qiu CP, Xing MT, Li M, Wang BF, Ye H, Shi JX, Dai LP, Wang X, Wang P*. Association of elevated autoantibody to high expression of GNAS in hepatocellular carcinoma. Heliyon, 2023, 9(12): e22627.

[8] Chen HL, Sun GY, Han Z, Wang HM, Li JQ, Ye H, Song CH, Zhang JY, Wang P*. Anti-CXCL8 autoantibodya potential diagnostic biomarker for esophageal squamous cell carcinoma. Medicina-Lithuania, 2022,58(10):1480.

[9] Xie WH, Sun GY, Zhu JC, Wang HM, Han Z, Wang P*. Anti-POSTN and anti-TIMP1 autoantibodies as diagnostic markers in esophageal squamous cell carcinoma. Frontiers in Genetics, 2022, 13: 860611.

[10] Li KM, Han Z, Wu JY, Ye H, Sun GY, Shi JX, Zhang JY, Wang P*. The Relationship between MALAT1 Polymorphism rs3200401 C > T and the Risk of Overall Cancer: A Meta-Analysis. Medicina-Lithuania, 2022,58(2):176.

[11] Yang Q, Qin JJ, Sun GY, Qin CP, Jiang D, Ye H, Wang X, Dai LP, Zhu JC, Wang P*, Jianying Zhang*. Discovery and validation of serum autoantibodies against tumor-associated antigens as biomarkers in gastric adenocarcinoma based on the focused protein arrays. Clinical and Translational Gastroenterology, 2021, 12(1): e00284.

[12] Wang HM, Yang XA, Sun GY, Yang Q, Cui C, Wang X, Ye H, Dai LP, Shi JX, Zhang JY, Wang P*. Identification and evaluation of autoantibody to a novel tumor-associated antigen GNA11 as a biomarker in esophageal squamous cell carcinoma. Frontiers in Oncology, 2021, 11:661043.

[13] Sun GY, Ye H, Wang, Cheng L, Ren PF, Shi JX, Dai LP, Wang P*, Jianying Zhang*. Identification of novel autoantibodies based on the protein chip encoded by cancer-driving genes in detection of esophageal squamous cell carcinoma. Oncoimmunology, 2020, 9(1): e1814515.

[14] Sun GY, Ye H, Wang X, Li TD, Jiang D, Qiu CP, Dai LP, Shi JX, Wang KJ, Song CH, Wang P*, Jianying Zhang*. Autoantibodies against tumor-associated antigens combined with microRNAs in detecting esophageal squamous cell carcinoma. Cancer Medicine, 2020, 9(3):1173-1182.

[15] Qin JJ, Yang Q, Ye H, Wang KY, Zhang M, Zhu JC, Wang X, Dai LP, Wang P*, Zhang JY*. Using serological proteome analysis to identify and evaluate anti-GRP78 autoantibody as biomarker in the detection of gastric cancer. Journal of Oncology, 2020, 2020: 9430737.


l 著作

[1] 王鹏(编委),罕见病临床与诊断(“十二五”国家科技支撑计划). 清华大学出版社(ISBN 978-7-302-46614-7),2017.

[2] 王鹏(编委、秘书),临床流行病学(医学高职高专“十二五”规划教材). 郑州大学出版社(ISBN:978-7-5645-1017-6),2012.


l 发明专利

[1] 王鹏(第一发明人),一种用于食管鳞癌辅助诊断的生物标志物及检测试剂盒;专利号:ZL 2021 1 1294764.2